Chamath Is Back With New SPAC, AI Scrutiny, China’s Moon Push | Pete DeJoy, Marty Kausas, Matteo Franceschetti, Abdul Al-Asaad, Derek Lo, Alex Telford
TBPN
00:00
The IPO Debate: New York vs. Texas and Global Business Communications
This chapter explores the implications of SpaceX's potential IPO location, comparing the benefits of going public on the NYSE versus in Texas. It also delves into international business communications, highlighting how different global cities facilitate professional interactions.
Transcript
Play full episode
Transcript
Episode notes
- (00:30) - Chamath is Back with New SPAC
- (31:33) - Timeline
- (01:01:23) - TBPN Substack
- (01:16:35) - Gong of the Day
- (01:26:14) - Timeline
- (01:59:29) - Pete DeJoy, co-founder and interim CEO of Astronomer, discusses the company's evolution from its inception in Cincinnati, Ohio, to becoming a leader in data orchestration with its Apache Airflow-powered platform, Astro. He highlights the company's significant growth, including a 292% year-over-year revenue increase and the relocation of their headquarters to New York City. DeJoy also addresses the recent media attention following the resignation of former CEO Andy Byron, emphasizing the team's resilience and commitment to their mission.
- (02:12:01) - Timeline
- (02:15:55) - China Heads to the Moon
- (02:21:46) - GPT-5 Facing a Reverse Deepseek Moment
- (02:30:57) - Marty Kausas, co-founder and CEO of Pylon, a B2B customer support platform, discusses the company's recent $31 million Series B funding co-led by Andreessen Horowitz and Bain Capital Ventures. He highlights Pylon's focus on the B2B market, emphasizing the complexity of support needs involving multiple teams and the necessity for comprehensive account context. Kausas also outlines Pylon's strategy to build a system of record from scratch, integrating AI agents to effectively manage intricate B2B support scenarios.
- (02:37:25) - Matteo Franceschetti, co-founder and CEO of Eight Sleep, announced the company's recent $100 million Series D funding, bringing total funding to $250 million. He highlighted the company's financial strength, noting they've been free cash flow positive for the past year, and outlined plans to enhance AI capabilities, pursue FDA approvals for sleep apnea and menopause-related products, and expand into the Asian market, particularly China.
- (02:44:03) - Abdul Al-Assad, co-founder and CEO of Basic Capital, discusses his company's mission to enable individuals to use credit for investing in financial assets rather than consumption. He highlights the recent $25 million Series A funding led by Kirsten at Code Runner and addresses public concerns about the risks of using credit to invest, emphasizing the importance of long-term investment horizons and the potential for wealth building through asset ownership. Abdul also contrasts Basic Capital's approach with traditional leveraged ETFs and margin loans, advocating for structured, long-term financing options to help individuals build wealth over time.
- (02:55:54) - Derek Lo, founder and CEO of Medallion, a provider network management platform, discusses the company's recent $43 million funding round led by Acrew Capital, with participation from Sequoia, Google Ventures, and Spark Capital. He explains how Medallion automates back-office processes for healthcare companies, focusing on managing clinical networks and streamlining tasks like credentialing and compliance. Lo also highlights the company's strategic decision to concentrate on healthcare-specific workflows rather than entering the competitive payroll space, emphasizing the importance of precision in their AI applications due to the critical nature of healthcare operations.
- (03:01:39) - Alex Telford, co-founder of Convoke, a biotech software startup, discusses their platform's aim to automate the knowledge work involved in drug development, focusing on planning and preparation to accelerate the process. He announces an $8.6 million seed funding led by Kleiner Perkins and shares his background as a life sciences consultant, emphasizing the potential of AI to enhance efficiency in the pharmaceutical industry. Telford also expresses skepticism about AI's role in patient recruitment, highlighting the challenges posed by the limited availability of patients for clinical trials.
TBPN.com is made possible by:
Ramp - https://ramp.com
Figma - https://figma.com
Vanta - https://vanta.com
Linear - https://linear.app
Eight Sleep - https://eightsleep.com/tbpn
Wander - https://wander.com/tbpn
Public - https://public.com
AdQuick - https://adquick.com
Bezel - https://getbezel.com
Numeral - https://www.numeralhq.com
Polymarket - https://polymarket.com
Attio - https://attio.com/tbpn
Fin - https://fin.ai/tbpn
Graphite - https://graphite.dev
Restream - https://restream.io
Profound - https://tryprofound.com
Julius AI - https://julius.ai
Follow TBPN:
https://TBPN.com
https://x.com/tbpn
https://open.spotify.com/show/2L6WMqY3GUPCGBD0dX6p00?si=674252d53acf4231
https://podcasts.apple.com/us/podcast/technology-brothers/id1772360235
https://www.youtube.com/@TBPNLive
The AI-powered Podcast Player
Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
